Anne Rachel Davis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anne Rachel Davis has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Carolyn L. Westhoff
1,2 Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY 10032, USA
2 shared publications- Carolyn L. Westhoff
Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY 10032, USA
2 shared publications Adela Camus
1 shared publicationAlison M. Pack
1 shared publication- Alison M. Pack
Department of Neurology, Columbia University, New York, NY, USA
1 shared publication - Amanda Dennis
Ibis Reproductive Health, Cambridge, Massachusetts
1 shared publication
Latest Publications
- 1 March 2016
- Published by Elsevier in Contraception
- Vol. 93 (3) , 263-265
Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year
- 1 March 2016
- Published by Elsevier in Contraception
- Vol. 93 (3) , 263-265
Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year
- 1 December 2015
- Published by Elsevier in Contraception
- Vol. 92 (6) , 578-584
A randomized controlled trial of daily text messages versus monthly paper diaries to collect bleeding data after intrauterine device insertion
- 1 December 2015
- Published by Elsevier in Contraception
- Vol. 92 (6) , 578-584
A randomized controlled trial of daily text messages versus monthly paper diaries to collect bleeding data after intrauterine device insertion
- Open Access
Carbamazepine coadministration with an oral contraceptive: Effects on steroid pharmacokinetics, ovulation, and bleeding
Summary: Purpose: Antiepileptic drugs (AEDs) are widely used in reproductive‐age women. The AED carbamazepine (CBZ) induces the hepatic cytochrome P450 system, thereby accelerating hormone metabolism. We sought to assess the pharmacodynamic effects of CBZ on breakthrough bleeding and ovulation during oral contraceptive (OC) use.Methods: A double‐blind, randomized, crossover study of healthy women ages 18–35 years. Participants took an OC containing 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) for 4 months. Concurrently, participants took 600 mg CBZ or a matching placebo for 2 months each, administered in random order. During the second month of CBZ or placebo, we measured EE and LNG levels 12 times over 24 h, ovarian follicular diameters with eight biweekly vaginal ultrasounds, weekly progesterone levels, and bleeding (using a diary).Key Findings: We enrolled 25 women; 10 completed the study. Five women discontinued because of reversible CBZ side effects. Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04). Ovulation occurred in 5 of 10 CBZ cycles compared to 1 of 10 placebo cycles (p = 0.06). Three or more days of breakthrough bleeding occurred during 8 of the 10 CBZ cycles compared to 2 of the 10 placebo cycles (p = 0.07).Significance: A commonly used dose of CBZ decreased levels of contraceptive steroids, increased breakthrough bleeding, and permitted ovulation during use of a low‐dose OC. Women treated with CBZ are not adequately protected from pregnancy by low‐dose OCs.
Open AccessCarbamazepine coadministration with an oral contraceptive: Effects on steroid pharmacokinetics, ovulation, and bleeding
Summary: Purpose: Antiepileptic drugs (AEDs) are widely used in reproductive‐age women. The AED carbamazepine (CBZ) induces the hepatic cytochrome P450 system, thereby accelerating hormone metabolism. We sought to assess the pharmacodynamic effects of CBZ on breakthrough bleeding and ovulation during oral contraceptive (OC) use.Methods: A double‐blind, randomized, crossover study of healthy women ages 18–35 years. Participants took an OC containing 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) for 4 months. Concurrently, participants took 600 mg CBZ or a matching placebo for 2 months each, administered in random order. During the second month of CBZ or placebo, we measured EE and LNG levels 12 times over 24 h, ovarian follicular diameters with eight biweekly vaginal ultrasounds, weekly progesterone levels, and bleeding (using a diary).Key Findings: We enrolled 25 women; 10 completed the study. Five women discontinued because of reversible CBZ side effects. Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04). Ovulation occurred in 5 of 10 CBZ cycles compared to 1 of 10 placebo cycles (p = 0.06). Three or more days of breakthrough bleeding occurred during 8 of the 10 CBZ cycles compared to 2 of the 10 placebo cycles (p = 0.07).Significance: A commonly used dose of CBZ decreased levels of contraceptive steroids, increased breakthrough bleeding, and permitted ovulation during use of a low‐dose OC. Women treated with CBZ are not adequately protected from pregnancy by low‐dose OCs.
- 1 October 2009
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 21 (5) , 390-395
Abortion in adolescents: epidemiology, confidentiality, and methods
To review the epidemiology, confidentiality, and methods of abortion provision specific to adolescents. In the United States, four out of five pregnancies in teenagers are unintended and about one-third of all adolescent pregnancies end in induced abortion. Barriers such as travel and cost decrease abortion access for all women and adolescents, whose pregnancies are diagnosed later than older women, may be particularly impacted by such challenges. An increasing majority of states require parental involvement in adolescents' decisions to end their pregnancies. Recent analyses indicate that mandating parental involvement does not promote family communication; rather, such laws may actually increase the risk of harm by delaying appropriate medical care. Medication and surgical abortion are options for adolescents; both are safe and effective. There is no evidence that abortion during adolescence causes negative psychological consequences, decreased fertility, or increased risk in future pregnancies. Continued high rates of unintended pregnancy among US adolescents necessitate access to safe and timely abortion services. Unfortunately, teens encounter unique barriers in obtaining abortion care that lead to delays and preventable risk associated with later abortion.
- 1 October 2009
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 21 (5) , 390-395
Abortion in adolescents: epidemiology, confidentiality, and methods
To review the epidemiology, confidentiality, and methods of abortion provision specific to adolescents. In the United States, four out of five pregnancies in teenagers are unintended and about one-third of all adolescent pregnancies end in induced abortion. Barriers such as travel and cost decrease abortion access for all women and adolescents, whose pregnancies are diagnosed later than older women, may be particularly impacted by such challenges. An increasing majority of states require parental involvement in adolescents' decisions to end their pregnancies. Recent analyses indicate that mandating parental involvement does not promote family communication; rather, such laws may actually increase the risk of harm by delaying appropriate medical care. Medication and surgical abortion are options for adolescents; both are safe and effective. There is no evidence that abortion during adolescence causes negative psychological consequences, decreased fertility, or increased risk in future pregnancies. Continued high rates of unintended pregnancy among US adolescents necessitate access to safe and timely abortion services. Unfortunately, teens encounter unique barriers in obtaining abortion care that lead to delays and preventable risk associated with later abortion.
- 1 June 2008
- Published by Elsevier in Contraception
- Vol. 77 (6) , 405-409
Reproductive history, sexual behavior and use of contraception in women with epilepsy
- 1 June 2008
- Published by Elsevier in Contraception
- Vol. 77 (6) , 405-409
Reproductive history, sexual behavior and use of contraception in women with epilepsy
- 1 May 2008
- Published by Elsevier in Fertility and Sterility
- Vol. 89 (5) , 1059-1063
Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive
- 1 May 2008
- Published by Elsevier in Fertility and Sterility
- Vol. 89 (5) , 1059-1063
Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive
- 1 January 2007
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 196 (1) , 31.e1-31.e7
Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure: results from a randomized trial
- 1 January 2007
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 196 (1) , 31.e1-31.e7
Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure: results from a randomized trial
- 1 October 2006
- Published by Elsevier in Journal of Adolescent Health
- Vol. 39 (4) , 607-609
Challenges of Conducting a Placebo-Controlled Trial for Dysmenorrhea in Adolescents
- 1 October 2006
- Published by Elsevier in Journal of Adolescent Health
- Vol. 39 (4) , 607-609
Challenges of Conducting a Placebo-Controlled Trial for Dysmenorrhea in Adolescents
- 1 July 2004
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 19 (7) , 1655-1658
Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure
Dilatation and curettage (D&C) has been the usual treatment for early pregnancy failure (EPF). Medical management with misoprostol may be an effective alternative. Bleeding patterns during and after medical management of EPF are unknown. A prospective cohort study was conducted at University-based clinics and physician offices. Eighty women <11 weeks estimated gestational age with a diagnosis of missed abortion or fetal demise were enrolled. Treatment consisted of either 800 micro g of moistened (2 ml of saline) or dry vaginal misoprostol. Self-reported bleeding and sanitary product usage were recorded in a daily 2 week diary. Haemoglobin was assessed at enrollment and 2 weeks later. After misoprostol treatment, patients reported bleeding or spotting every day for the 14 days observed. Self-assessed heavy bleeding days were few (median 3) and usually occurred immediately after treatment. Sanitary pad use was highly variable (mean 30.5, range 2-125 pads over the 2 week period) and not related to changes in haemoglobin. The mean decrease in haemoglobin was 0.5 g/dl (SD 1.2). Complete expulsion without D&C occurred in 85% of subjects. Bleeding for at least 2 weeks after vaginal misoprostol for EPF is common. Heavy bleeding is usually limited to a few days after treatment. Clinically important changes in haemoglobin are rare.
- 1 July 2004
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 19 (7) , 1655-1658
Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure
Dilatation and curettage (D&C) has been the usual treatment for early pregnancy failure (EPF). Medical management with misoprostol may be an effective alternative. Bleeding patterns during and after medical management of EPF are unknown. A prospective cohort study was conducted at University-based clinics and physician offices. Eighty women <11 weeks estimated gestational age with a diagnosis of missed abortion or fetal demise were enrolled. Treatment consisted of either 800 micro g of moistened (2 ml of saline) or dry vaginal misoprostol. Self-reported bleeding and sanitary product usage were recorded in a daily 2 week diary. Haemoglobin was assessed at enrollment and 2 weeks later. After misoprostol treatment, patients reported bleeding or spotting every day for the 14 days observed. Self-assessed heavy bleeding days were few (median 3) and usually occurred immediately after treatment. Sanitary pad use was highly variable (mean 30.5, range 2-125 pads over the 2 week period) and not related to changes in haemoglobin. The mean decrease in haemoglobin was 0.5 g/dl (SD 1.2). Complete expulsion without D&C occurred in 85% of subjects. Bleeding for at least 2 weeks after vaginal misoprostol for EPF is common. Heavy bleeding is usually limited to a few days after treatment. Clinically important changes in haemoglobin are rare.